MYH9-related disorders display heterogeneous kidney involvement and outcome
Nahid Tabibzadeh(Sorbonne Paris Cité), Philippe Vanhille(Centre Hospitalier de Valenciennes), Arnaud Lionet(Metabolism and Renal Physiology), François Vrtovsnik(Assistance Publique – Hôpitaux de Paris), D. Labatut(Centre Hospitalier de Niort), Nicole Schlegel(Inserm), D. Fleury(Centre Hospitalier de Valenciennes), Frank Bridoux(Université de Poitiers), Noémie Jourde‐Chiche(Aix-Marseille Université)
Cited by 37
Related Papers
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases
|Kidney International|2021|809
The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group
|Nature Reviews Nephrology|2018|544
Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant
|Blood|2012|543
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis
|New England Journal of Medicine|2007|520